Ginseng for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ginseng for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
复制标题
DOI：
10.2174/1568026615666150813143753
复制
发表时间：
2015-10
影响因子：
3.4
通讯作者：
Yu-yi Wang;Guoyan Yang;J. Gong;Fang Lu;Qing-chun Diao;Jin Sun;Kang Zhang;Jinzhou Tian;Jianpin Liu
中科院分区：
文献类型：
--
作者：
Yu-yi Wang;Guoyan Yang;J. Gong;Fang Lu;Qing-chun Diao;Jin Sun;Kang Zhang;Jinzhou Tian;Jianpin Liu
背景阿尔茨海默病（AD）没有治愈性治疗。人参在亚洲国家被广泛用于治疗AD。目的评价人参治疗AD的有效性和安全性。我们检索了7个主要数据库中关于人参治疗AD的随机临床试验（RCT），从开始到2014年12月。采用科克伦偏倚风险工具评价方法学质量。我们使用RevMan 5.2来合成结果。结果：本次系统评价共纳入4项随机对照试验，涉及259名受试者。纳入研究的方法学质量并不乐观。所有的比较都是在联合治疗（人参加常规治疗）与常规治疗之间进行的。荟萃分析和几项个体研究的结果表明，通过MMSE、ADAS-cog、ADAS-noncog和CDR测量的联合治疗的有效性不一致。没有研究报告生活质量（QoL）的结局。当前数据未报告严重不良事件。结论人参对AD的影响目前尚无定论。现有研究的主要局限性是样本量小、方法质量差和没有安慰剂对照。未来需要更大规模的精心设计的研究来测试人参对AD的影响。
BACKGROUND There is no curative treatment for Alzheimer's disease (AD). Ginseng is widely used in the treatment of AD in Asian countries. OBJECTIVE To evaluate the effectiveness and safety of ginseng for AD. METHODS We searched seven main databases for randomized clinical trials (RCTs) on ginseng for AD from their inception to December 2014. The Cochrane risk of bias tool was used to assess the methodological quality. We used RevMan 5.2 to synthesize the results. RESULTS Four RCTs involving 259 participants were identified for this systematic review. The methodological quality of included studies was not promising. All comparisons were made between combined treatment (ginseng plus conventional treatment) versus conventional treatment. The results of meta-analyses and several individual studies showed that the effectiveness of combined treatment was inconsistent as measured by MMSE, ADAS-cog, ADAS-noncog, and CDR. No studies reported the outcomes of quality of life (QoL). The current data did not report serious adverse events. CONCLUSION This review showed that the effects of ginseng on AD were still inconclusive. The main limitations of the available studies were small sample sizes, poor methodological qualities and no placebo controls. Larger, well-designed studies are needed to test the effect of ginseng on AD in the future.